Clinical evaluation of the simultaneous determination of tumor markers in fluid and serum and their ratio in the differential diagnosis of serous effusions

Tumor Biology

Volumn 25, Issue 5-6, 2004, Pages 276-281

  Trapé, Jaume ^a   Molina, Rafael ^b   Sant, Francesc ^a  

^a Althaia   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Cytokeratin 19; Effusions; Malignant effusions; Tumor markers

Indexed keywords

CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19; TUMOR MARKER;

ARTICLE; ASCITES; CONTROLLED STUDY; CYTOLOGY; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; MESOTHELIUM; PLEURA EFFUSION; PLEURA FLUID; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; STATISTICAL SIGNIFICANCE;

EID: 11444268393     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081392     Document Type: Article

References (23)

1. Light RW: Approach to the patient; in Light RW (ed): Pleural Diseases. Philadelphia, Lea & Febiger, 1990, pp 75-83.
2. Runyon BA: Care of patients with ascites. N Engl J Med 1994;330:337-342.
3. Garcia-Pachon E, Padilla-Navas I, Dosada D, Miralles-Llopis A: Elevated levels of carcinoembryonic antigen in nonmalignant pleural effusions. Chest 1997;111:643-647.
4. Fenton KN, Richardson JD: Diagnosis and management of malignant pleural effusions. Am J Surg 1995;170:69-74.
5. Romero S, Fernández C, Arriero JM, Espasa A, Candela A, Martin C, Sánchez-Payá J: CEA, CA 15-3 and CYFRA 21-1 in serum and pleural fluid of patients with pleural effusions. Eur Respir J 1996;9:17-23.
6. Sánchez de Cos J, López Parra S, Disdier Vicente C, Martín Vicente MJ, Masa Jiménez JF, Domínguez Retortillo C: Utilidad del antígeno carcinoembrionario, enolasa neuron específica y antígeno de células escamosas (en líquido pleural y suero) en el diagnóstico del derrame pleural maligno. An Med Interna 1996;13:369-373.
7. Marel M, Stastny B, Melinova L, Svandova E, Light RW: Diagnosis of pleural effusions. Experience with clinical studies 1986 to 1990. Chest 1995;107:1589-1603.
8. Ferroni P, Szpak C, Greiner JW, Simpson JF, Guadagni F, Johnston WW, Colcher D: CA 72-4 radioimmunoassay in the diagnosis of malignant effusions. Comparison of various tumor markers. Int J Cancer 1990;46:445-451.
9. Saoth H, Sumi M, Yagyu H, Ishikawa H, Suyama T, Naitoh T, Saitoh T, Hasegawa S: Clinical evaluation of CYFRA 21-1 in malignant pleural fluids. Oncology 1995;52:211-214.
10. San Jose ME, Alvarez D, Valdes L, Sarandeses A, Valle JM, Penela P: Utility of tumour markers in the diagnosis of neoplastic pleural effusions. Clin Chim Acta 1997;265:193-205.
11. Miédougé M, Salama G, Barange K, Vincent C, Vinel JP, Serre G: Evaluation of alpha-fetoprotein assay in ascitic fluid for the diagnosis of hepatocellular carcinoma. Clin Chim Acta 1999;280:161-171.
12. Molina R, Filella X, Jo J, Bruix J, Ballesta AM: Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases. Clin Chem 1991;37:1379-1383.
13. Crespí S, Vilimelis J, Moragues M, Mayol A, Molina R: El diagnóstico de malignidad en los derrames serosos mediante el uso marcadores tumorales: Utilidad de la determinación simultanea (líquido/suero); in Molina R, Ballesta AM (eds): Biología y utilidad clínica de los marcadores tumorales. Sant Quirze del Vallès, Gràfiques Sant Quirze, 1999, vol 1, pp 240-242.
14. Miédougé M, Rouzaud P, Salama G, Pujazon MC, Vincent C, Mauduyl MA, Reyer P, Carles C, Serre G: Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions. Br J Cancer 1999;81:1059-1061.
15. Salama G, Miédougé M, Rouzaud P, Mauduyl MA, Pujazon MC, Vincent C, Carles P, Serre G: Evaluation of pleural CYFRA 21-1 and carcinoembryonic antigen in the diagnosis of malignant pleural effusions. Br J Cancer 1998;77:472-476.
16. Toumbis M, Rasidakis A, Passalidou E, Kalomenidis J, Alchanatis M, Orphanidou D, Jordanoglou J: Evaluation of CYFRA 21-1 in malignant and benign pleural effusions. Anticancer Res 1996;2101-2104.
17. Ferrer J, Villarino MA, Encabo G, Felip E, Bermejo B, Vilà S, Orriols R: Diagnostic utility of CYFRA 21-1, carcinoembryonic antigen, CA 125, neuron specific enolase and squamous cell antigen level determinations in the serum and pleural fluid of patients with pleural effusions. Cancer 1999;86:1488-1495.
18. Villena V, Lopez-Encuentra, Echave-Sustaeta J, Martin-Escribano P, Ortuño de Solo B, Estenoz-Alfaro J: Diagnostic value of CA 72-4, carcinoembryonic antigen, CA15-3 and CA 19-9 assay in pleural fluid. Cancer 1996;78:736-740.
19. Gulyás M, Kaposi AD, Elek G, Szollár, Hjerpe A: Value of carcinoembryonic (CEA) and cholesterol assays of ascitic fluid in of inconclusive cytology. J Clin Pathol 2001;54:831-835.
20. Villena V, Lopez-Encuentra A, Echave Sustaeta J, Martin-Escribano P, Ortuño-de-Solo B, Estenoz Alfaro J: Diagnostic value of CA 549 in pleural fluid. Comparison with CEA, CA 15.3 and CA 72.4. Lung Cancer 2003;40:289-294.
21. Mackay AM, Tracy RP, Craighead JE: Cytokeratin expression in rat mesothelial cells in vitro is controlled by extracellular matrix. J Cell Sci 1990;5:97-107.
22. ZeillermarkerAM, Verbreugh HA, Hoynck van Papendrecht AA, Leguit P: CA 125 secretion by peritoneal mesothelial cells. J Clin Pathol 1994;47:263-265.
23. Kuralay F, Tokgöz Z, Cömlekci A: Diagnostic usefulness of tumour marker levels in pleural effusions of malignant and benign origin. Clin Chim Acta 2000;300:43-55.